Click here for international medical scientific information about Oncology for Healthcare Professionals.
Click here for general international information for patients, caregivers and the general public.
Country-specific medical scientific information for Healthcare Professionals.
This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information
Boehringer Ingelheim is committed to addressing some of society’s most challenging healthcare issues. We want to share our knowledge and encourage clinical advances, which is why we maintain a presence at key congresses including ASCO, ELCC, WCLC and ESMO. Find out more about our activities at the following oncology congresses.
* Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
**Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: May 2018
